A phase III placebo-controlled comparative study of SJP-0118 in patients with bacterial conjunctivitis
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs SJP 0118 (Primary)
- Indications Conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Senju Pharmaceutical
- 18 Oct 2018 Status changed from active, no longer recruiting to completed.
- 18 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.